Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Pfizer
Information provided by (Responsible Party):
Pfizer Identifier:
First received: June 4, 2009
Last updated: November 4, 2014
Last verified: November 2014

The study will be investigating pharmacokinetics, safety and efficacy in patients less than 12 years of age with severe hemophilia A that have been previously treated with Factor VIII products ( including blood products).

Condition Intervention Phase
Hemophilia A
Biological: Moroctocog alfa ( AF-CC)
Procedure: Laboratory tests
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Non-randomized, Open-label Study To Evaluate The Pharmacokinetics, Safety, And Efficacy Of Refacto Af In Previously Treated Subjects Less Than Twelve Years Of Age With Severe Hemophilia A (Fviii:c <1%).

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Incidence of clinically significant FVIII inhibitor development. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Annualized bleeding rates (ABRs) in subjects receiving treatment with ReFacto AF. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Responses to the first on-demand treatment with ReFacto AF for all new bleeds (4 point scale of assessment) as assessed by the parent/legal representative. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Number of ReFacto AF infusions to treat each new bleed. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Number of bleeds within 48 hours of a preventive/prophylaxis dose of ReFacto AF. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Average infusion dose and total factor consumption, and the incidence of less-than-expected therapeutic effect (LETE). [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Incidence of SAEs and nonserious AEs. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: December 2009
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Moroctocog alfa (AF-CC)
Open Label
Biological: Moroctocog alfa ( AF-CC)
Dosing is at the discretion of the Investigator
Other Name: ReFacto AF
Procedure: Laboratory tests
Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody


Ages Eligible for Study:   up to 11 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male subjects less than 12 years of age with a documented history of severe hemophilia A (FVIII:C less than 1%).
  • Subjects who are less than 6 years of age must have had at least 50 Exposure Days (EDs) to prior FVIII products (including blood products).
  • Subjects who are equal to or greater than 6 years of age must have had greater than 150 EDs to prior FVIII products (including blood products).

Exclusion Criteria:

  • For laboratory assessments, any measured Bethesda inhibitor titer equal to or greater than 0.6 BU, regardless of the laboratory normal range, or any Bethesda inhibitor titer greater than ULN for the testing laboratory at the time of screening.
  • Any other bleeding disorder in addition to hemophilia A.
  • Treatment with any investigational drug or device within 30 days before the time of signing the parental informed consent/assent form.
  • Major surgery planned to occur during the course of the study.
  • Regular (e.g., daily; every other day) use of agents or medications known to influence platelet function such as aspirin or certain nonsteroidal anti-inflammatory drugs (NSAIDS).
  • Regular, concomitant therapy with immunomodulating drugs (e.g., intravenous immunoglobulin [IVIG], routine systemic corticosteroids), or currently receiving immune tolerance induction (ITI) for inhibitor treatment.
  • The subject is receiving treatment for HIV or hepatitis infection (unless the subject is on a stable antiviral regimen [i.e., consistent treatment regimen for at least 3 months before the parental informed consent/assent form is signed]).
  • Platelet count less than 100,000/µL.
  • Prothrombin time (PT) equal to or greater than 1.25 x ULN, or international normalized ratio (INR) equal to or greater than 1.5.
  • Known hypersensitivity to hamster protein.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00914459

Contact: Pfizer Call Center 1-800-718-1021

Kuopio University Hospital, Department of Pedriatrics Active, not recruiting
Kuopio, Finland, 70211
LTD Medinvesti- Institute of hematology and transfuziology Recruiting
Tbilisi, Georgia, 0177'
155 Papadiamantopoulou Str & Thivon Str. Recruiting
Athens, Greece, 11527
A' University Clinic of Paediatrics Recruiting
Thessaloniki, Greece, 546 42
Universita degli Studi di Parma Active, not recruiting
Parma, Italy, 43100
Spitalul Clinic Judetean de Urgenta Craiova Recruiting
Craiova, Dolj, Romania, 200642
Sanador Active, not recruiting
Bucuresti, Romania, 011026
Mother and Child Health Care Institute "Dr Vukan Cupic" Recruiting
Belgrade, Serbia, 11070
University Children's Hospital Recruiting
Belgrade, Serbia, 11000
Hospital de Jerez de la Frontera Servicio de Hematologia Terminated
Jerez de la Frontera, Cádiz, Spain, 11407
Complexo Hospitalario Juan Canalejo Recruiting
A Coruna, Spain, 15006
Hospital Universitario Puerta del Mar Active, not recruiting
Cadiz, Spain, 11009
Hospital La Paz Active, not recruiting
Madrid, Spain, 28046
Hospital Universitario Central de Asturias Recruiting
Oviedo, Spain, 33006
Hospital Miguel Servet Active, not recruiting
Zaragoza, Spain, 50009
Karolinska Universitetssjukhuset-Solna Active, not recruiting
Stockholm, Sweden, 171 76
Cukurova Universitesi Tip Fakultesi Recruiting
Adana, Balcali, Turkey, 01330
Akdeniz Universitesi Tip Fakultesi Recruiting
Antalya, Turkey, 07059
Ege Universitesi Tip Fakultesi Recruiting
Bornova/Izmir, Turkey, 35100
State institution "The Institute of blood pathology and transfusion medicine of AMS of Ukraine" Recruiting
Lviv, Ukraine, 79044
Oblasna Klinichna Dytiacha Likarnia, Hematolohichne Viddilennia Recruiting
Zaporizhzhia, Ukraine, 69063
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT00914459     History of Changes
Other Study ID Numbers: 3082B2-4433, B1831005, 2008-008435-29
Study First Received: June 4, 2009
Last Updated: November 4, 2014
Health Authority: European Union: European Medicines Agency

Keywords provided by Pfizer:
hemophilia A

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
Genetic Diseases, Inborn
Hematologic Diseases
Hemorrhagic Disorders
Factor VIII
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on November 20, 2014